Better Benefit-to-Risk Ratio for Anti-CGRP mAbs Than Current Migraine Preventive Medication
The researchers compared anti-CGRP mAbs with other drugs for the prevention of episodic and chronic migraine using a likelihood to help versus harm analysis.